Protective effect of Thiocolchicoside against Haloperidol Induced Orofacial Dyskinesia and Catalepsy in Rats

The goal of the current study was to assess thiocolchicoside’s impact on catalepsy and orofacial dyskinesia in wistar male albino rats that had been induced by haloperidol. The neurodegenerative illness known as catalepsy, whose cause is unclear, is typified by motor symptoms such as bradykinesia, tremor, rigidity in the muscles, and instability in one’s posture. It’s a disorder marked by a tendency to remain motionless, a decrease in reactivity to stimuli and inactivity. The inability to adjust one’s posture in response to external signals is known as catalepsy. Tardive dyskinesia is an iatrogenic illness defined by late-onset hyperkinetic involuntary dyskinesia, usually affecting the orofacial region, caused by long-term use of classical neuroleptics. Neuroleptics causes blockade of dopaminergic (DA) transmission produces catalepsy. Haloperidol blocks dopamine D2 receptors and reduces dopaminergic transmission in the basal ganglia, which puts animals in a state of catalepsy. The anticataleptic study was carried out on animal model such as haloperidol induced orofacial dyskinesia and catalepsy. Animals of this model were treated with std. drug levodopa/carbidopa (125mg/kg) and test drug thiocolchicoside low dose (4mg/kg), high dose (8mg/kg). The persistent injection of haloperidol to rats resulted in a considerable increase in catalepsy, tongue protrusions, and vacuous chewing motions (VCMs). These results indicate that thiocolchicoside possess anticataleptic effect against haloperidol induced catalepsy in rats. The results indicated strong anticataleptic efficacy, suggesting that thiocolchicoside may be useful in the treatment of catalepsy.